Search

Now showing items 1-9 of 9

Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry.

Chang, P; Fonarow, GC; Freeman, J; Gersh, Bernard John; Go, AS; Jackson, Larry Ronald II; Kim, SH; ... (14 authors) (Clin Cardiol, 2016-02)

BACKGROUND: Patients with sinus node dysfunction (SND) have increased risk of atrial tachyarrhythmias, including atrial fibrillation (AF). To date, treatment patterns and outcomes of patients with SND and AF have not been ...

Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Ansell, J; Chang, P; Fonarow, GC; Gersh, Bernard John; Kim, S; Kowey, Peter R; Mahaffey, Kenneth William; ... (13 authors) (Circulation, 2015-02-03)

BACKGROUND: Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions ...

Contemporary trends and predictors of postacute service use and routine discharge home after stroke.

Prvu Bettger, Janet; McCoy, L; Smith, EE; Fonarow, GC; Schwamm, LH; Peterson, Eric David (J Am Heart Assoc, 2015-02-23)

BACKGROUND: Returning home after the hospital is a primary aim for healthcare; however, additional postacute care (PAC) services are sometimes necessary for returning stroke patients to their pre-event status. Recent trends ...

Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke.

Britz, GW; Constable, M; Cox, M; Fonarow, GC; Lin, CB; Olson, DaiWai M; Peterson, Eric David; ... (9 authors) (J Am Heart Assoc, 2015-07-22)

BACKGROUND: Timely thrombolytic therapy can improve stroke outcomes. Nevertheless, the ability of US hospitals to meet guidelines for intravenous tissue plasminogen activator (tPA) remains suboptimal. What is unclear is ...

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, Bernard John; Holmes, DaJuanicia; Hylek, EM; ... (15 authors) (J Am Heart Assoc, 2013-11-25)

BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns ...

Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure.

Fonarow, GC; Get With the Guidelines Steering Committee and Hospitals; Hernandez, Adrian Felipe; Liang, L; Peterson, Eric David; Piccini, Jonathan Paul Sr; Thomas, Kevin Lindsey; ... (8 authors) (J Am Heart Assoc, 2013-09-26)

BACKGROUND: The intersection of heart failure (HF) and atrial fibrillation (AF) is common, but the burden of AF among black patients with HF is poorly characterized. We sought to determine the prevalence of AF, characteristics, ...

Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.

Das, S; de Lemos, JA; Fonarow, GC; Peng, SA; Peterson, Eric David; Vora, Amit Navin; Wang, TY (J Am Heart Assoc, 2016-01-21)

BACKGROUND: While aldosterone antagonists have proven benefit among post-myocardial infarction (MI) patients with low ejection fraction (EF), how this treatment is used among older MI patients in routine practice is not ...

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF).

Chang, P; Fonarow, GC; Gersh, Bernard John; Holmqvist, Fredrik Nils; Hylek, E; Kim, S; Kowey, Peter R; ... (15 authors) (J Am Heart Assoc, 2015-09-14)

BACKGROUND: Most patients with atrial fibrillation (AF) require rate control; however, the optimal target heart rate remains under debate. We aimed to assess rate control and subsequent outcomes among patients with permanent ...

Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.

Al-Khatib, Sana Mustapha; Anstrom, Kevin J; Bhatt, DL; Curtis, Lesley H; Fonarow, GC; Heidenreich, Paul A; Hellkamp, Anne; ... (12 authors) (J Am Heart Assoc, 2015-08-06)

BACKGROUND: Implantable cardioverter-defibrillator (ICD) therapy is associated with improved outcomes in patients with heart failure (HF), but whether this association holds among older patients with multiple comorbid illnesses ...